why choose us

First received: October 27, 2022

Clinical Trial: VS-6766+Abema+Fulv in Met HR+/HER- BC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Single Arm Phase 1/2 Trial of Abemaciclib + VS-6766 + Fulvestrant in Metastatic HR+/HER2- Breast Cancer

Brief Summary: This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer.The names of the study drugs involved in this study are:VS-6766AbemaciclibFulvestrant

Read more